Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Want to see IN:GLENMARK full AI Analyst Report?
GLENMARK Stock Chart & Stats
₹2065.95
-₹29.45(-1.81%)
At close: 4:00 PM EST
₹2065.95
-₹29.45(-1.81%)
Day’s Range― - ―
52-Week Range₹1,372.00 - ₹2,471.05
Previous CloseN/A
Volume301.32K
Average Volume (3M)28.97K
Market Cap
₹670.97B
Enterprise Value₹657.13B
Total Cash (Recent Filing)₹29.58B
Total Debt (Recent Filing)₹12.24B
Price to Earnings (P/E)35.6
Beta0.52
Next Earnings
May 29, 2026EPS Estimate
18.2Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)35.78
Shares Outstanding282,200,800
10 Day Avg. Volume44,119
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.81
Price to Sales (P/S)3.19
P/FCF Ratio-27.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)81.8
Revenue Forecast (FY)₹159.47B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~25% revenue growth demonstrates expanding market share and product uptake across franchises. Over a 2–6 month horizon this underpins scale benefits, supports reinvestment in R&D and manufacturing, and provides a structural revenue base to absorb short-term margin swings.
Diversified Business ModelPresence across finished-dosage formulations, API manufacturing and active R&D creates multiple durable revenue channels. Vertical integration and geographic diversification reduce single-market exposure and provide structural resilience to regulatory or pricing shocks over the medium term.
Stable Core Operating MarginsConsistent EBIT/EBITDA margins signal operational efficiency in manufacturing and commercialization. Stable operating profitability is a durable advantage that supports cash generation potential and competitive pricing flexibility even when net income fluctuates.
Bears Say
High LeverageRelatively high debt versus equity increases interest and refinancing risk and reduces strategic flexibility. If operating cash flow pressures persist, leverage can constrain capex, M&A or R&D funding and amplify downside in a stressed liquidity environment over the coming months.
Negative Operating Cash FlowNegative operating and free cash flow indicate the business is not self-funding capital needs, forcing reliance on external financing. This weakens liquidity, hampers deleveraging or reinvestment plans, and raises the risk of funding squeezes if credit conditions tighten.
Profitability VolatilityVolatile net margins and inconsistent net income reduce earnings predictability and complicate planning for R&D, dividends, and debt servicing. For creditors and investors this increases perceived risk and may limit access to stable long-term financing options.
Glenmark Pharmaceuticals Limited News
GLENMARK FAQ
What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1372.00 and its highest was ₹2471.05 in the past 12 months.
What is Glenmark Pharmaceuticals Limited’s market cap?
Glenmark Pharmaceuticals Limited’s market cap is ₹670.97B.
When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
Glenmark Pharmaceuticals Limited’s upcoming earnings report date is May 29, 2026 which is in 8 days.
How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
Glenmark Pharmaceuticals Limited released its earnings results on Jan 30, 2026. The company reported ₹14.28 earnings per share for the quarter, missing the consensus estimate of ₹18.7 by -₹4.42.
Is Glenmark Pharmaceuticals Limited overvalued?
According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Overvalued.
Does Glenmark Pharmaceuticals Limited pay dividends?
Glenmark Pharmaceuticals Limited pays a Monthly dividend of ₹2.5 which represents an annual dividend yield of 0.24%. See more information on Glenmark Pharmaceuticals Limited dividends here
What is Glenmark Pharmaceuticals Limited’s EPS estimate?
Glenmark Pharmaceuticals Limited’s EPS estimate is 18.2.
How many shares outstanding does Glenmark Pharmaceuticals Limited have?
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding.
What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
Glenmark Pharmaceuticals Limited reported an EPS of ₹14.28 in its last earnings report, missing expectations of ₹18.7. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLENMARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Biocon Limited
―
GlaxoSmithKline Pharmaceuticals Limited
―
Lupin Limited
―